J. C. Castaño-Osorio, Alejandra María Giraldo-García, M. Giraldo
{"title":"登革热病毒疫苗的现状","authors":"J. C. Castaño-Osorio, Alejandra María Giraldo-García, M. Giraldo","doi":"10.5772/INTECHOPEN.80820","DOIUrl":null,"url":null,"abstract":"Dengue is a disease caused by the dengue virus (DENV), being the most important arbovirus in the world. About 3.97 billion people live in countries at risk and 400 million infections occur each year, of which 500,000 suffer from the most severe form of the disease and 25,000 of these die. The clinical spectrum of Dengue ranges from asymptomatic infection to severe Dengue characterized by increased vascular permeability, bleeding disorders, shock, and death. The increase in global cases of this disease is due in part to the absence of effective public intervention measures and lack of a specific treatment and vaccines licensed for human use. Therefore, in this review, we will present the different strategies known to date for the development of vaccines for this disease, as well as the results and limitations obtained in the different clinical studies.","PeriodicalId":330741,"journal":{"name":"Dengue Fever - a Resilient Threat in the Face of Innovation","volume":"32 1","pages":"0"},"PeriodicalIF":0.0000,"publicationDate":"2018-11-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"10","resultStr":"{\"title\":\"Current Status of Vaccines against Dengue Virus\",\"authors\":\"J. C. Castaño-Osorio, Alejandra María Giraldo-García, M. Giraldo\",\"doi\":\"10.5772/INTECHOPEN.80820\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"Dengue is a disease caused by the dengue virus (DENV), being the most important arbovirus in the world. About 3.97 billion people live in countries at risk and 400 million infections occur each year, of which 500,000 suffer from the most severe form of the disease and 25,000 of these die. The clinical spectrum of Dengue ranges from asymptomatic infection to severe Dengue characterized by increased vascular permeability, bleeding disorders, shock, and death. The increase in global cases of this disease is due in part to the absence of effective public intervention measures and lack of a specific treatment and vaccines licensed for human use. Therefore, in this review, we will present the different strategies known to date for the development of vaccines for this disease, as well as the results and limitations obtained in the different clinical studies.\",\"PeriodicalId\":330741,\"journal\":{\"name\":\"Dengue Fever - a Resilient Threat in the Face of Innovation\",\"volume\":\"32 1\",\"pages\":\"0\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2018-11-05\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"10\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Dengue Fever - a Resilient Threat in the Face of Innovation\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.5772/INTECHOPEN.80820\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Dengue Fever - a Resilient Threat in the Face of Innovation","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.5772/INTECHOPEN.80820","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
Dengue is a disease caused by the dengue virus (DENV), being the most important arbovirus in the world. About 3.97 billion people live in countries at risk and 400 million infections occur each year, of which 500,000 suffer from the most severe form of the disease and 25,000 of these die. The clinical spectrum of Dengue ranges from asymptomatic infection to severe Dengue characterized by increased vascular permeability, bleeding disorders, shock, and death. The increase in global cases of this disease is due in part to the absence of effective public intervention measures and lack of a specific treatment and vaccines licensed for human use. Therefore, in this review, we will present the different strategies known to date for the development of vaccines for this disease, as well as the results and limitations obtained in the different clinical studies.